Observational studyThe oncologist2024

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.

Giulia Pasello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.